TABLE 3.
Summary of selected clinical reports of stereotactic magnetic resonance adaptive radiation therapy (SMART) for tumors in the abdomen and pelvis
| Study | Median f/u (months) | Patients | Treatment site | Treatment regimen | Median BED10 | Local control | Overall survival | Severe† acute toxicity | Severe† late toxicity |
|---|---|---|---|---|---|---|---|---|---|
| Rosenberg et al.42 | 21.2 | 26 | Liver | 50Gy (range 30–60) in 5 fx (range 6–12) | 100 | 80.4% (at median f/u) | 1 year 69%, 2 year 60% | NA | 7.7% (at median f/u) |
| Henke et al.18 | 15 | 20 | Various abdominal sites | 50Gy (range 50–60) in 5 fx (range 4–5) | 100 | 90% (at median f/u) | 1 year 75% | 0% | 0% |
| Luterstein et al.43 | 15.8 | 17 | Hepatobiliary | 40Gy (40–50) in 5 fx (range 3–5) | 72 | 1 year 85.6%, 2 year 73.3% | 1 year 76%, 2 year 46.1% | 6% | 0% |
| Bruynzeel et al.22 | 1.5 | 101 | Prostate (localized) | 36.25Gy in 5 fx | 62.5 | NA | NA | GU: 5.9% GI: 0% | NA |
Abbreviations: f/u, follow‐up; Fx, fraction; GI, gastrointestinal; GU, genitourinary; NA, not available.
†
Severe defined as CTCAE grade three or higher.